Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

Wilson I. Gonsalves, Francis K. Buadi, Sikander Ailawadhi, P. Leif Bergsagel, Asher A. Chanan Khan, David Dingli, Angela Dispenzieri, Rafael Fonseca, Susan R. Hayman, Prashant Kapoor, Taxiarchis V. Kourelis, Martha Q. Lacy, Jeremy T. Larsen, Eli Muchtar, Craig B. Reeder, Taimur Sher, A. Keith Stewart, Rahma Warsame, Ronald S. Go, Robert A. KyleNelson Leung, Yi Lin, John A. Lust, Stephen J. Russell, Stephen R. Zeldenrust, Amie L. Fonder, Yi L. Hwa, Miriam A. Hobbs, Angela A. Mayo, William J. Hogan, S. Vincent Rajkumar, Shaji K. Kumar, Morie A. Gertz, Vivek Roy

Research output: Contribution to journalReview article

20 Scopus citations


Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.

Original languageEnglish (US)
Pages (from-to)353-367
Number of pages15
JournalBone Marrow Transplantation
Issue number3
StatePublished - Mar 1 2019


ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this